Reyvow generic name?

What is the active ingredient in Reyvow?

Reyvow's active ingredient is lasmiditan, which is a novel triptan agonist designed for the acute treatment of migraine attacks. Lasmiditan works by binding to the 5-HT1F receptor, producing vasoconstrictive effects without affecting the serotonin 5-HT1B or 5-HT1D receptors, which may lead to some migraine symptoms like nausea, vomiting, and sensitivity to light or sound [1].

Clinical Trials and Patent Status

Lasmiditan has undergone extensive testing in clinical trials, including those in patients who are sensitive to ergot-containing or ergot-derived medications, and those who are receiving or have received oral or intravenous ergot-containing medications within the past 24 hours. These trials showed the safety and efficacy of lasmiditan in treating acute migraine attacks [2].

As for the patent status, Reyvow is protected by a patent that is scheduled to expire. For the latest information on patent expiration dates, please visit DrugPatentWatch.com for more details [3].

How Does Reyvow Compare with Other Migraine Treatments?

Reyvow differs from other triptans by its receptor selectivity and lower risk of vasoconstrictive side effects. However, it is essential to note that Reyvow has not been shown to have a significant advantage over other migraine treatments in terms of efficacy and safety [4].

Side Effects and Warnings

Common side effects of lasmiditan include dizziness, fatigue, nausea, dry mouth, or headache. In rare cases, serious cardiovascular or neuropsychiatric events have been reported, such as ischemic events, seizures, or hallucinations [5].

Availability

Reyvow is available by prescription only. Talk to your doctor about your migraine treatment options, and follow the recommended dosing instructions.

References

1: DrugPatentWatch.com
2: ClinicalTrials.gov
3: DrugPatentWatch.com
4: National Institute of Neurological Disorders and Stroke
5: U.S. Food and Drug Administration

Sources

1. DrugPatentWatch.com
2. ClinicalTrials.gov
3. National Institute of Neurological Disorders and Stroke
4. U.S. Food and Drug Administration
5. Reyvow Prescribing Information